

Female Contraception - Pipeline Review, H1 2020

<https://marketpublishers.com/r/FCF6526F9C7EN.html>

Date: June 2020

Pages: 92

Price: US\$ 2,000.00 (Single User License)

ID: FCF6526F9C7EN

Abstracts

Female Contraception - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Contraception - Pipeline Review, H1 2020, provides an overview of the Female Contraception (Women's Health) pipeline landscape.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 3, 13 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).

The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Female Contraception (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Female Contraception (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Female Contraception (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Female Contraception (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Female Contraception - Overview
- Female Contraception - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Female Contraception - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Female Contraception - Companies Involved in Therapeutics Development
- Adare Pharmaceuticals Inc
- Agile Therapeutics Inc
- Dare Bioscience Inc
- Evestra Inc
- Exeltis Pharmaceuticals Holding SL
- Hervana Ltd
- Luye Pharma Group Ltd
- MedinCell SA
- Micron Biomedical Inc
- Mithra Pharmaceuticals SA
- Mucommune LLC
- Navad Life Sciences Pte Ltd
- Orion Biotechnology Canada Ltd
- Ovastasis LLC
- Teva Pharmaceutical Industries Ltd
- Viramal Ltd
- Yaso Therapeutics Inc
- YourChoice Therapeutics Inc
- Female Contraception - Drug Profiles
- (dienogest + ethinylestradiol) PR - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress**(drospirenone + estetrol) - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****(estradiol + segesterone acetate) - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****(ethinylestradiol + gestodene) ER - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****AG-200 ER - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****AG-200 SP - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Female Contraception - Dormant Projects****Female Contraception - Discontinued Products****Female Contraception - Product Development Milestones****Featured News & Press Releases****May 20, 2020: Mithra and Searchlight Pharma announce filing of New Drug Submission for Estelle in Canada****Apr 22, 2020: MedinCell launches regulatory development of mdc-WWM program****Apr 16, 2020: Mayne Pharma submits New Drug Application for E4/DRSP to the FDA****Mar 03, 2020: Mithra receives acceptance of marketing authorization application (MAA) to market Estelle in Belgium and Luxembourg****Feb 27, 2020: EMA accepts Richter's Marketing Authorization Application for Estelle, a novel combined oral contraceptive****Feb 10, 2020: Mithra's E4-based product Estelle to benefit from positive ruling on Patent Income Deduction****Dec 05, 2019: Once-A-month oral contraceptive pill in development****Nov 28, 2019: MedinCell receives \$19 million grant for its mdc-WWM program****Oct 22, 2019: Mithra announces publication of Estelle abstracts in connection with the 13th Annual Meeting of the European Society of Gynecology**

Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology

Aug 08, 2019: Mithra obtains crucial additional Estelle patent in Japan

Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary nationwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results

Apr 02, 2019: Mithra wins essencia Innovation Award 2019 for its new generation contraceptive pill, Estelle

Feb 13, 2019: Mithra successfully produces its first commercial batch of Myring for Europe

Jan 30, 2019: Mithra announces positive top-line results of Estelle phase III oral contraceptive study in U.S/Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Female Contraception, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Female Contraception - Pipeline by Adare Pharmaceuticals Inc, H1 2020
Female Contraception - Pipeline by Agile Therapeutics Inc, H1 2020
Female Contraception - Pipeline by Dare Bioscience Inc, H1 2020
Female Contraception - Pipeline by Evestra Inc, H1 2020
Female Contraception - Pipeline by Exeltis Pharmaceuticals Holding SL, H1 2020
Female Contraception - Pipeline by Hervana Ltd, H1 2020
Female Contraception - Pipeline by Luye Pharma Group Ltd, H1 2020
Female Contraception - Pipeline by MedinCell SA, H1 2020
Female Contraception - Pipeline by Micron Biomedical Inc, H1 2020
Female Contraception - Pipeline by Mithra Pharmaceuticals SA, H1 2020
Female Contraception - Pipeline by Mucommune LLC, H1 2020
Female Contraception - Pipeline by Navad Life Sciences Pte Ltd, H1 2020
Female Contraception - Pipeline by Orion Biotechnology Canada Ltd, H1 2020
Female Contraception - Pipeline by Ovastasis LLC, H1 2020
Female Contraception - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
Female Contraception - Pipeline by Viramal Ltd, H1 2020
Female Contraception - Pipeline by Yaso Therapeutics Inc, H1 2020
Female Contraception - Pipeline by YourChoice Therapeutics Inc, H1 2020
Female Contraception - Dormant Projects, H1 2020
Female Contraception - Dormant Projects, H1 2020 (Contd..1), H1 2020
Female Contraception - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Female Contraception, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Adare Pharmaceuticals Inc
Agile Therapeutics Inc
Dare Bioscience Inc
Evestra Inc
Exeltis Pharmaceuticals Holding SL
Hervana Ltd
Luye Pharma Group Ltd
MedinCell SA
Micron Biomedical Inc
Mithra Pharmaceuticals SA
Mucommune LLC
Navad Life Sciences Pte Ltd
Orion Biotechnology Canada Ltd
Ovastasis LLC
Teva Pharmaceutical Industries Ltd
Viramal Ltd
Yaso Therapeutics Inc
YourChoice Therapeutics Inc

I would like to order

Product name: Female Contraception - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/FCF6526F9C7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FCF6526F9C7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970